BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G, Poussin K, Zucman-Rossi J. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med. 2011;208:1359-1366. [PMID: 21690253 DOI: 10.1084/jem.20110283] [Cited by in Crossref: 176] [Cited by in F6Publishing: 166] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu C, Mu X, Wang X, Zhang C, Zhang L, Yu B, Sun G. Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling. Molecules 2019;24:E1363. [PMID: 30959969 DOI: 10.3390/molecules24071363] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
2 Bellamy COC, Maxwell RS, Prost S, Azodo IA, Powell JJ, Manning JR. The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre: Hepatocellular adenomas. Histopathology 2013;62:431-45. [DOI: 10.1111/his.12011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
3 Sosonkina N, Starenki D, Park JI. The Role of STAT3 in Thyroid Cancer. Cancers (Basel) 2014;6:526-44. [PMID: 24662939 DOI: 10.3390/cancers6010526] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
4 Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, Garbers C, Rose-john S, Floss DM, Scheller J. Constitutively Active Mutant gp130 Receptor Protein from Inflammatory Hepatocellular Adenoma Is Inhibited by an Anti-gp130 Antibody That Specifically Neutralizes Interleukin 11 Signaling. Journal of Biological Chemistry 2012;287:13743-51. [DOI: 10.1074/jbc.m112.349167] [Cited by in Crossref: 26] [Article Influence: 2.6] [Reference Citation Analysis]
5 Moser B, Edtmayer S, Witalisz-Siepracka A, Stoiber D. The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia. Biomedicines 2021;9:1051. [PMID: 34440253 DOI: 10.3390/biomedicines9081051] [Reference Citation Analysis]
6 Ernst M, Putoczki TL. Stat3: Linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol 2012;39:711-8. [DOI: 10.1111/j.1440-1681.2011.05659.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kumagawa M, Matsumoto N, Watanabe Y, Hirayama M, Miura T, Nakagawara H, Ogawa M, Matsuoka S, Moriyama M, Takayama T, Sugitani M. Contrast-enhanced ultrasonographic findings of serum amyloid A-positive hepatocellular neoplasm: Does hepatocellular adenoma arise in cirrhotic liver? World J Hepatol 2016; 8(26): 1110-1115 [PMID: 27660679 DOI: 10.4254/wjh.v8.i26.1110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18:374-384. [PMID: 28323260 DOI: 10.1038/ni.3691] [Cited by in Crossref: 376] [Cited by in F6Publishing: 365] [Article Influence: 75.2] [Reference Citation Analysis]
9 Vogel TP, Milner JD, Cooper MA. The Ying and Yang of STAT3 in Human Disease. J Clin Immunol 2015;35:615-23. [PMID: 26280891 DOI: 10.1007/s10875-015-0187-8] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 12.4] [Reference Citation Analysis]
10 Lamertz L, Floss DM, Scheller J. Combined deletion of the fibronectin-type III domains and the stalk region results in ligand-independent, constitutive activation of the Interleukin 6 signal-transducing receptor gp130. Cytokine 2018;110:428-34. [DOI: 10.1016/j.cyto.2018.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Hu T, Yeh JE, Pinello L, Jacob J, Chakravarthy S, Yuan GC, Chopra R, Frank DA. Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity. Mol Cell Biol 2015;35:3284-300. [PMID: 26169829 DOI: 10.1128/MCB.00060-15] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
12 Zhang A, Wang P, Sun H, Yan G, Han Y, Wang X. High-throughput ultra-performance liquid chromatography-mass spectrometry characterization of metabolites guided by a bioinformatics program. Mol BioSyst 2013;9:2259. [DOI: 10.1039/c3mb70171a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
13 Blanc JF, Frulio N, Chiche L, Bioulac-Sage P, Balabaud C. Hepatocellular adenoma management: advances but still a long way to go. Hepat Oncol. 2015;2:171-180. [PMID: 30190996 DOI: 10.2217/hep.14.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics. 2013;12:489-498. [PMID: 23943603 DOI: 10.1093/bfgp/elt028] [Cited by in Crossref: 193] [Cited by in F6Publishing: 185] [Article Influence: 21.4] [Reference Citation Analysis]
15 Yang J, Kunimoto H, Katayama B, Zhao H, Shiromizu T, Wang L, Ozawa T, Tomonaga T, Tsuruta D, Nakajima K. Phospho-Ser727 triggers a multistep inactivation of STAT3 by rapid dissociation of pY705-SH2 through C-terminal tail modulation. Int Immunol 2020;32:73-88. [PMID: 31555812 DOI: 10.1093/intimm/dxz061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Feng T, Cao W, Shen W, Zhang L, Gu X, Guo Y, Tsai HI, Liu X, Li J, Zhang J, Li S, Wu F, Liu Y. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. Oncotarget 2017;8:329-44. [PMID: 27861147 DOI: 10.18632/oncotarget.13393] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
17 Diallo M, Herrera F. The role of understudied post-translational modifications for the behavior and function of Signal Transducer and Activator of Transcription 3. FEBS J 2021. [PMID: 34235865 DOI: 10.1111/febs.16116] [Reference Citation Analysis]
18 Song H, Yang Z, Jiang M, Zhang G, Gao Y, Shen Z, Wu Z, Lou Y. Target-catalyzed hairpin structure-mediated padlock cyclization for ultrasensitive rolling circle amplification. Talanta 2019;204:29-35. [DOI: 10.1016/j.talanta.2019.05.057] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
19 Zhou Z, Wang M, Li J, Xiao M, Chin YE, Cheng J, Yeh ET, Yang J, Yi J. SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer. Oncogene 2016;35:5826-38. [PMID: 27181202 DOI: 10.1038/onc.2016.124] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
20 Schmidt-arras D, Müller M, Stevanovic M, Horn S, Schütt A, Bergmann J, Wilkens R, Lickert A, Rose-john S. Oncogenic deletion mutants of gp130 signal from intracellular compartments. Journal of Cell Science. [DOI: 10.1242/jcs.130294] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
21 Jeric I, Maurer G, Cavallo AL, Raguz J, Desideri E, Tarkowski B, Parrini M, Fischer I, Zatloukal K, Baccarini M. A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. Nat Commun 2016;7:13781. [PMID: 28000790 DOI: 10.1038/ncomms13781] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
22 Bedossa P, Paradis V, Zucman-rossi J. Cellular and Molecular Techniques. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 88-110. [DOI: 10.1016/b978-0-7020-6697-9.00002-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Saarimäki-vire J, Balboa D, Russell MA, Saarikettu J, Kinnunen M, Keskitalo S, Malhi A, Valensisi C, Andrus C, Eurola S, Grym H, Ustinov J, Wartiovaara K, Hawkins RD, Silvennoinen O, Varjosalo M, Morgan NG, Otonkoski T. An Activating STAT3 Mutation Causes Neonatal Diabetes through Premature Induction of Pancreatic Differentiation. Cell Reports 2017;19:281-94. [DOI: 10.1016/j.celrep.2017.03.055] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 11.2] [Reference Citation Analysis]
24 Tolomeo M, Cascio A. The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy. Int J Mol Sci 2021;22:E603. [PMID: 33435349 DOI: 10.3390/ijms22020603] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Carson R, Celtikci B, Fenning C, Javadi A, Crawford N, Carbonell LP, Lawler M, Longley DB, Johnston PG, Van Schaeybroeck S. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. Clin Cancer Res 2015;21:3230-40. [PMID: 25813020 DOI: 10.1158/1078-0432.CCR-14-2701] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
26 Avalle L, Camporeale A, Morciano G, Caroccia N, Ghetti E, Orecchia V, Viavattene D, Giorgi C, Pinton P, Poli V. STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca2+ fluxes and apoptotic responses. Cell Death Differ 2019;26:932-42. [PMID: 30042492 DOI: 10.1038/s41418-018-0171-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
27 Lokau J, Garbers C. Activating mutations of the gp130/JAK/STAT pathway in human diseases. Adv Protein Chem Struct Biol 2019;116:283-309. [PMID: 31036294 DOI: 10.1016/bs.apcsb.2018.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
28 Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015;519:57-62. [PMID: 25731159 DOI: 10.1038/nature14228] [Cited by in Crossref: 394] [Cited by in F6Publishing: 359] [Article Influence: 56.3] [Reference Citation Analysis]
29 Wang X, Wang B, Zhou L, Wang X, Veeraraghavan VP, Mohan SK, Xin F. Ganoderma lucidum put forth anti-tumor activity against PC-3 prostate cancer cells via inhibition of Jak-1/STAT-3 activity. Saudi J Biol Sci 2020;27:2632-7. [PMID: 32994721 DOI: 10.1016/j.sjbs.2020.05.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Lee J, Kim JC, Lee SE, Quinley C, Kim H, Herdman S, Corr M, Raz E. Signal transducer and activator of transcription 3 (STAT3) protein suppresses adenoma-to-carcinoma transition in Apcmin/+ mice via regulation of Snail-1 (SNAI) protein stability. J Biol Chem 2012;287:18182-9. [PMID: 22496368 DOI: 10.1074/jbc.M111.328831] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
31 Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opinion on Therapeutic Targets 2013;17:1303-28. [DOI: 10.1517/14728222.2013.830105] [Cited by in Crossref: 39] [Cited by in F6Publishing: 61] [Article Influence: 4.3] [Reference Citation Analysis]
32 Giraldez MD, Carneros D, Garbers C, Rose-John S, Bustos M. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34211157 DOI: 10.1038/s41575-021-00473-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Geletu M, Guy S, Arulanandam R, Feracci H, Raptis L. Engaged for survival: From cadherin ligation to STAT3 activation. JAKSTAT 2013;2:e27363. [PMID: 24470979 DOI: 10.4161/jkst.27363] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
34 Pan YR, Chen CC, Chan YT, Wang HJ, Chien FT, Chen YL, Liu JL, Yang MH. STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas. Nat Commun 2018;9:3696. [PMID: 30209389 DOI: 10.1038/s41467-018-06134-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
35 de Araujo ED, Orlova A, Neubauer HA, Bajusz D, Seo HS, Dhe-Paganon S, Keserű GM, Moriggl R, Gunning PT. Structural Implications of STAT3 and STAT5 SH2 Domain Mutations. Cancers (Basel) 2019;11:E1757. [PMID: 31717342 DOI: 10.3390/cancers11111757] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
36 European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol. 2016;65:386-398. [PMID: 27085809 DOI: 10.1016/j.jhep.2016.04.001] [Cited by in Crossref: 201] [Cited by in F6Publishing: 153] [Article Influence: 33.5] [Reference Citation Analysis]
37 Huynh J, Chand A, Gough D, Ernst M. Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map. Nat Rev Cancer 2019;19:82-96. [DOI: 10.1038/s41568-018-0090-8] [Cited by in Crossref: 144] [Cited by in F6Publishing: 146] [Article Influence: 36.0] [Reference Citation Analysis]
38 Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology. 2014;26:54-74. [PMID: 24552665 DOI: 10.1016/j.smim.2014.01.001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 319] [Article Influence: 39.9] [Reference Citation Analysis]
39 Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgeirsson SS, Clément B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 2012;72:2533-2542. [PMID: 22419664 DOI: 10.1158/0008-5472.can-11-3317] [Cited by in Crossref: 133] [Cited by in F6Publishing: 67] [Article Influence: 13.3] [Reference Citation Analysis]
40 Bahal S, Houssen ME, Manson A, Lorenzo L, Russell MA, Morgan NG, Tahami F, Grigoriadou S. Evidence that a STAT3 Mutation Causing Hyper IgE Syndrome Leads to Repression of Transcriptional Activity. Case Reports Immunol 2019;2019:1869524. [PMID: 31737384 DOI: 10.1155/2019/1869524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Bruserud Ø, Nepstad I, Hauge M, Hatfield KJ, Reikvam H. STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. Expert Rev Hematol 2015;8:29-41. [PMID: 25374305 DOI: 10.1586/17474086.2015.971005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
42 Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207-221. [PMID: 25065853 DOI: 10.1016/j.ccr.2014.05.019] [Cited by in Crossref: 330] [Cited by in F6Publishing: 323] [Article Influence: 41.3] [Reference Citation Analysis]
43 Pelletier L, Rebouissou S, Vignjevic D, Bioulac-Sage P, Zucman-Rossi J. HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines. BMC Cancer 2011;11:427. [PMID: 21975049 DOI: 10.1186/1471-2407-11-427] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
44 Okada Y, Watanabe T, Shoji T, Taguchi K, Ogo N, Asai A. Visualization and quantification of dynamic STAT3 homodimerization in living cells using homoFluoppi. Sci Rep 2018;8:2385. [PMID: 29402895 DOI: 10.1038/s41598-018-20234-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Goltz D, Fischer HP. [Hepatocellular tumours in noncirrhotic liver tissue]. Pathologe 2015;36:597-606; quiz 607-8. [PMID: 26496997 DOI: 10.1007/s00292-015-0113-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Kirchmeyer M, Servais FA, Hamdorf M, Nazarov PV, Ginolhac A, Halder R, Vallar L, Glanemann M, Rubie C, Lammert F, Kreis S, Behrmann I. Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. J Leukoc Biol 2018;104:987-1002. [DOI: 10.1002/jlb.ma1217-499rr] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
47 Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4:2218. [PMID: 23887712 DOI: 10.1038/ncomms3218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Chalaris A, Schmidt-Arras D, Yamamoto K, Rose-John S. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Dig Dis. 2012;30:492-499. [PMID: 23108305 DOI: 10.1159/000341698] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
49 Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault J, Couchy G, Laurent A, Balabaud C, Bioulac‐sage P, Zucman‐rossi J. Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression. Hepatology 2016;64:2047-61. [DOI: 10.1002/hep.28638] [Cited by in Crossref: 127] [Cited by in F6Publishing: 123] [Article Influence: 21.2] [Reference Citation Analysis]
50 Kuusanmäki H, Dufva O, Parri E, van Adrichem AJ, Rajala H, Majumder MM, Yadav B, Parsons A, Chan WC, Wennerberg K, Mustjoki S, Heckman CA. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget 2017;8:97516-27. [PMID: 29228628 DOI: 10.18632/oncotarget.22178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
51 Schütt A, Zacharias M, Schneider N, Horn S, Grötzinger J, Rose-john S, Schmidt-arras D. gp130 activation is regulated by D2–D3 interdomain connectivity. Biochemical Journal 2013;450:487-96. [DOI: 10.1042/bj20121660] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
52 Beaufrère A, Paradis V. Hepatocellular adenomas: review of pathological and molecular features. Hum Pathol 2021;112:128-37. [PMID: 33307077 DOI: 10.1016/j.humpath.2020.11.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Miyakoshi M, Yamamoto M, Tanaka H, Ogawa K. Serine 727 phosphorylation of STAT3: an early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine. Mol Carcinog 2014;53:67-76. [PMID: 22911886 DOI: 10.1002/mc.21949] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
54 Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette G. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25:428-441. [PMID: 24735922 DOI: 10.1016/j.ccr.2014.03.005] [Cited by in Crossref: 178] [Cited by in F6Publishing: 147] [Article Influence: 22.3] [Reference Citation Analysis]
55 Araki T, Watanabe Y, Okada Y, Murakami H, Ogo N, Asai A. Identification of serum and glucocorticoid-regulated kinase 1 as a regulator of signal transducer and activator of transcription 3 signaling. Exp Cell Res 2022;:113079. [PMID: 35202674 DOI: 10.1016/j.yexcr.2022.113079] [Reference Citation Analysis]
56 Wake MS, Watson CJ. STAT3 the oncogene - still eluding therapy? FEBS J 2015;282:2600-11. [DOI: 10.1111/febs.13285] [Cited by in Crossref: 125] [Cited by in F6Publishing: 129] [Article Influence: 17.9] [Reference Citation Analysis]
57 Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W, Lewis MT, Dave B, Chang JC, Landis MD, Creighton CJ, Mancini MA, Tweardy DJ. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene 2015;34:1341-53. [PMID: 24681959 DOI: 10.1038/onc.2014.72] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 11.0] [Reference Citation Analysis]
58 Nault J, Ningarhari M, Rebouissou S, Zucman-rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol 2019;16:544-58. [DOI: 10.1038/s41575-019-0165-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 18.3] [Reference Citation Analysis]
59 Li L, Lorzadeh A, Hirst M. Regulatory variation: an emerging vantage point for cancer biology: Regulatory variation in cancer. WIREs Syst Biol Med 2014;6:37-59. [DOI: 10.1002/wsbm.1250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Lundgren S, Keränen MAI, Kankainen M, Huuhtanen J, Walldin G, Kerr CM, Clemente M, Ebeling F, Rajala H, Brück O, Lähdesmäki H, Hannula S, Hannunen T, Ellonen P, Young NS, Ogawa S, Maciejewski JP, Hellström-Lindberg E, Mustjoki S. Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia 2021;35:1365-79. [PMID: 33785863 DOI: 10.1038/s41375-021-01231-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
61 Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 2016;35:939-51. [DOI: 10.1038/onc.2015.150] [Cited by in Crossref: 129] [Cited by in F6Publishing: 123] [Article Influence: 18.4] [Reference Citation Analysis]
62 Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022. [PMID: 34982503 DOI: 10.1111/liv.15152] [Reference Citation Analysis]
63 Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol 2014;26:38-47. [PMID: 24602448 DOI: 10.1016/j.smim.2014.01.008] [Cited by in Crossref: 273] [Cited by in F6Publishing: 271] [Article Influence: 34.1] [Reference Citation Analysis]
64 Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422-1433. [PMID: 23788652 DOI: 10.1101/gr.154492.113] [Cited by in Crossref: 314] [Cited by in F6Publishing: 310] [Article Influence: 34.9] [Reference Citation Analysis]
65 Parri E, Kuusanmäki H, van Adrichem AJ, Kaustio M, Wennerberg K. Identification of novel regulators of STAT3 activity. PLoS One 2020;15:e0230819. [PMID: 32231398 DOI: 10.1371/journal.pone.0230819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
66 Demaria M, Camporeale A, Poli V. STAT3 and metabolism: How many ways to use a single molecule?: STAT3 and Metabolism. Int J Cancer 2014;135:1997-2003. [DOI: 10.1002/ijc.28767] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
67 Beebe JD, Liu J, Zhang J. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacology & Therapeutics 2018;191:74-91. [DOI: 10.1016/j.pharmthera.2018.06.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 16.3] [Reference Citation Analysis]
68 Borghouts C, Delis N, Brill B, Weiss A, Mack L, Lucks P, Groner B. A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells. JAKSTAT 2012;1:44-54. [PMID: 24058750 DOI: 10.4161/jkst.18947] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
69 Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, Garbers C, Rose-John S, Floss DM, Scheller J. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem 2012;287:13743-51. [PMID: 22523320 DOI: 10.1074/jbc.M111.349167] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
70 Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G; European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies”. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015;27:516-32. [PMID: 25873174 DOI: 10.1016/j.ccell.2015.03.006] [Cited by in Crossref: 247] [Cited by in F6Publishing: 241] [Article Influence: 35.3] [Reference Citation Analysis]
71 Joseph NM, Ferrell LD, Jain D, Torbenson MS, Wu TT, Yeh MM, Kakar S. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma. Mod Pathol 2014;27:62-72. [PMID: 23807780 DOI: 10.1038/modpathol.2013.114] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
72 Calderaro J, Labrune P, Morcrette G, Rebouissou S, Franco D, Prévot S, Quaglia A, Bedossa P, Libbrecht L, Terracciano L. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol. 2013;58:350-357. [PMID: 23046672 DOI: 10.1016/j.jhep.2012.09.030] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
73 Vilarinho S, Erson-Omay EZ, Mitchell-Richards K, Cha C, Nelson-Williams C, Harmancı AS, Yasuno K, Günel M, Taddei TH. Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination. J Hepatol 2017;67:186-91. [PMID: 28323122 DOI: 10.1016/j.jhep.2017.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
74 Sasaki M, Yoneda N, Sawai Y, Imai Y, Kondo F, Fukusato T, Yoshikawa S, Kobayashi S, Sato Y, Matsui O. Clinicopathological characteristics of serum amyloid A-positive hepatocellular neoplasms/nodules arising in alcoholic cirrhosis. Histopathology. 2015;66:836-845. [PMID: 25318388 DOI: 10.1111/his.12588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
75 Poussin K, Pilati C, Couchy G, Calderaro J, Bioulac-Sage P, Bacq Y, Paradis V, Leteurtre E, Sturm N, Ramos J. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology. 2013;2:e27090. [PMID: 24501689 DOI: 10.4161/onci.27090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
76 Bioulac-Sage P, Sempoux C, Balabaud C. Hepatocellular adenoma: Classification, variants and clinical relevance. Semin Diagn Pathol. 2017;34:112-125. [PMID: 28131467 DOI: 10.1053/j.semdp.2016.12.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
77 Rinis N, Küster A, Schmitz-Van de Leur H, Mohr A, Müller-Newen G. Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies. Cell Commun Signal. 2014;12:14. [PMID: 24612692 DOI: 10.1186/1478-811x-12-14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
78 Bise S, Frulio N, Hocquelet A, Alberti N, Blanc JF, Laurent C, Laumonier H, Balabaud C, Bioulac-Sage P, Trillaud H. New MRI features improve subtype classification of hepatocellular adenoma. Eur Radiol 2019;29:2436-47. [PMID: 30523457 DOI: 10.1007/s00330-018-5784-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
79 Teramo A, Gattazzo C, Passeri F, Lico A, Tasca G, Cabrelle A, Martini V, Frezzato F, Trimarco V, Ave E, Boscaro E, Piazza F, Facco M, Trentin L, Semenzato G, Zambello R. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood 2013;121:3843-54, S1. [PMID: 23515927 DOI: 10.1182/blood-2012-07-441378] [Cited by in F6Publishing: 48] [Reference Citation Analysis]
80 Mori R, Wauman J, Icardi L, Van der Heyden J, De Cauwer L, Peelman F, De Bosscher K, Tavernier J. TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional activity. Sci Rep 2017;7:15919. [PMID: 29162862 DOI: 10.1038/s41598-017-15912-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
81 Liu N, He S, Tolbert E, Gong R, Bayliss G, Zhuang S. Suramin alleviates glomerular injury and inflammation in the remnant kidney. PLoS One 2012;7:e36194. [PMID: 22558380 DOI: 10.1371/journal.pone.0036194] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
82 Jenkins BJ. Transcriptional regulation of pattern recognition receptors by Jak/STAT signaling, and the implications for disease pathogenesis. J Interferon Cytokine Res 2014;34:750-8. [PMID: 25051239 DOI: 10.1089/jir.2014.0081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
83 Riebeling T, Staab J, Herrmann-Lingen C, Meyer T. DNA binding reduces the dissociation rate of STAT1 dimers and impairs the interdimeric exchange of protomers. BMC Biochem 2014;15:28. [PMID: 25526807 DOI: 10.1186/s12858-014-0028-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Herrera SC, Bach EA. JAK/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates. Development 2019;146:dev167643. [PMID: 30696713 DOI: 10.1242/dev.167643] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
85 Sasaki M, Nakanuma Y. Overview of hepatocellular adenoma in Japan. Int J Hepatol 2012;2012:648131. [PMID: 22973519 DOI: 10.1155/2012/648131] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
86 Demaria M, Misale S, Giorgi C, Miano V, Camporeale A, Campisi J, Pinton P, Poli V. STAT3 can serve as a hit in the process of malignant transformation of primary cells. Cell Death Differ 2012;19:1390-7. [PMID: 22402588 DOI: 10.1038/cdd.2012.20] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
87 Melenhorst JJ. LGL: a disease rediscovered. Blood 2012;120:2932-3. [PMID: 23065007 DOI: 10.1182/blood-2012-08-448514] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
88 Groner B, Vafaizadeh V. Cytokine regulation of mammary gland development and epithelial cell functions through discrete activities of Stat proteins. Mol Cell Endocrinol 2014;382:552-9. [PMID: 24076095 DOI: 10.1016/j.mce.2013.08.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
89 Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J, Saint-Paul MC, De Muret A, Redon MJ, Buffet C, Salenave S, Balabaud C, Prevot S, Labrune P, Bioulac-Sage P, Scoazec JY, Chanson P, Zucman-Rossi J. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol. 2012;56:184-191. [PMID: 21835143 DOI: 10.1016/j.jhep.2011.07.018] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 7.7] [Reference Citation Analysis]
90 Rajala HL, Olson T, Clemente MJ, Lagström S, Ellonen P, Lundan T, Hamm DE, Zaman SA, Lopez Marti JM, Andersson EI, Jerez A, Porkka K, Maciejewski JP, Loughran TP, Mustjoki S. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica 2015;100:91-9. [PMID: 25281507 DOI: 10.3324/haematol.2014.113142] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
91 Nakagawa H, Fujita M, Fujimoto A. Genome sequencing analysis of liver cancer for precision medicine. Semin Cancer Biol 2019;55:120-7. [PMID: 29605648 DOI: 10.1016/j.semcancer.2018.03.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
92 Letra-Vilela R, Cardoso B, Silva-Almeida C, Maia Rocha A, Murtinheira F, Branco-Santos J, Rodriguez C, Martin V, Santa-Marta M, Herrera F. Can asymmetric post-translational modifications regulate the behavior of STAT3 homodimers? FASEB Bioadv 2020;2:116-25. [PMID: 32123861 DOI: 10.1096/fba.2019-00049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, Pang WL, Kizhakeyil A, Wijaya GC, Huang DC, Nagarajan S, Chia BK, Cheah D, Liu YH, Zhang F, Rao HL, Tang T, Wong EK, Bei JX, Iqbal J, Grigoropoulos NF, Ng SB, Chng WJ, Teh BT, Tan SY, Verma NK, Fan H, Lim ST, Ong CK. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood 2018;132:1146-58. [PMID: 30054295 DOI: 10.1182/blood-2018-01-829424] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 23.5] [Reference Citation Analysis]
94 Olson KC, Moosic KB, Jones MK, Larkin PMK, Olson TL, Toro MF, Fox TE, Feith DJ, Loughran TP Jr. Large granular lymphocyte leukemia serum and corresponding hematological parameters reveal unique cytokine and sphingolipid biomarkers and associations with STAT3 mutations. Cancer Med 2020;9:6533-49. [PMID: 32710512 DOI: 10.1002/cam4.3246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
95 Zhang HF, Lai R. STAT3 in Cancer-Friend or Foe? Cancers (Basel). 2014;6:1408-1440. [PMID: 24995504 DOI: 10.3390/cancers6031408] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
96 Rajala HL, Porkka K, Maciejewski JP, Loughran TP Jr, Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med 2014;46:114-22. [PMID: 24512550 DOI: 10.3109/07853890.2014.882105] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
97 Hahn E, Putra J. Hepatocellular adenoma in the paediatric population: Molecular classification and clinical associations. World J Gastroenterol 2020; 26(19): 2294-2304 [PMID: 32476794 DOI: 10.3748/wjg.v26.i19.2294] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Fukusato T, Soejima Y, Kondo F, Inoue M, Watanabe M, Takahashi Y, Aso T, Uozaki H, Sano K, Sanada Y, Niki T. Preserved or enhanced OATP1B3 expression in hepatocellular adenoma subtypes with nuclear accumulation of β-catenin. Hepatol Res 2015;45:E32-42. [PMID: 25418671 DOI: 10.1111/hepr.12453] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
99 Ryu J, Kang M, Lee MS, Kim HJ, Nam SH, Song HE, Lee D, Lee JW. Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells. Mol Cell Biol 2014;34:2946-60. [PMID: 24912675 DOI: 10.1128/MCB.00660-14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
100 Han J, van den Heuvel MC, Kusano H, de Jong KP, Gouw AS. How normal is the liver in which the inflammatory type hepatocellular adenoma develops? Int J Hepatol 2012;2012:805621. [PMID: 23024866 DOI: 10.1155/2012/805621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
101 Böhmer FD, Friedrich K. Protein tyrosine phosphatases as wardens of STAT signaling. JAKSTAT 2014;3:e28087. [PMID: 24778927 DOI: 10.4161/jkst.28087] [Cited by in Crossref: 32] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
102 Kasembeli M, Lau WC, Roh SH, Eckols TK, Frydman J, Chiu W, Tweardy DJ. Modulation of STAT3 folding and function by TRiC/CCT chaperonin. PLoS Biol 2014;12:e1001844. [PMID: 24756126 DOI: 10.1371/journal.pbio.1001844] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
103 Kiel MJ, Sahasrabuddhe AA, Rolland DCM, Velusamy T, Chung F, Schaller M, Bailey NG, Betz BL, Miranda RN, Porcu P, Byrd JC, Medeiros LJ, Kunkel SL, Bahler DW, Lim MS, Elenitoba-Johnson KSJ. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome. Nat Commun 2015;6:8470. [PMID: 26415585 DOI: 10.1038/ncomms9470] [Cited by in Crossref: 113] [Cited by in F6Publishing: 114] [Article Influence: 16.1] [Reference Citation Analysis]
104 Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology. 2013;144:888-902. [PMID: 23485860 DOI: 10.1053/j.gastro.2013.02.032] [Cited by in Crossref: 199] [Cited by in F6Publishing: 145] [Article Influence: 22.1] [Reference Citation Analysis]
105 Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012;1:58-70. [PMID: 22724089 DOI: 10.3978/j.issn.2224-4778.2011.11.02] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
106 Bioulac-sage P, Cubel G, Taouji S, Scoazec J, Leteurtre E, Paradis V, Sturm N, Van Nhieu JT, Wendum D, Bancel B, Ramos J, Paraf F, Saint Paul MC, Michalak S, Fabre M, Guettier C, Le Bail B, Zucman-rossi J, Balabaud C. Immunohistochemical Markers on Needle Biopsies Are Helpful for the Diagnosis of Focal Nodular Hyperplasia and Hepatocellular Adenoma Subtypes. American Journal of Surgical Pathology 2012;36:1691-9. [DOI: 10.1097/pas.0b013e3182653ece] [Cited by in Crossref: 89] [Cited by in F6Publishing: 25] [Article Influence: 8.9] [Reference Citation Analysis]
107 Andersson E, Kuusanmäki H, Bortoluzzi S, Lagström S, Parsons A, Rajala H, van Adrichem A, Eldfors S, Olson T, Clemente MJ, Laasonen A, Ellonen P, Heckman C, Loughran TP, Maciejewski JP, Mustjoki S. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia 2016;30:1204-8. [PMID: 26419508 DOI: 10.1038/leu.2015.263] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
108 Castain C, Sempoux C, Brunt EM, Causse O, Heitzmann A, Hernandez-prera JC, Le Bail B, Schirmacher P, Thung SN, Balabaud C, Bioulac-sage P. Coexistence of inflammatory hepatocellular adenomas with HNF1α-inactivated adenomas: is there an association? Histopathology 2014;64:890-5. [DOI: 10.1111/his.12326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
109 Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 2016;64:1403-1415. [PMID: 26867490 DOI: 10.1016/j.jhep.2016.02.004] [Cited by in Crossref: 305] [Cited by in F6Publishing: 300] [Article Influence: 50.8] [Reference Citation Analysis]
110 Todoric J, Antonucci L, Karin M. Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev Res (Phila) 2016;9:895-905. [PMID: 27913448 DOI: 10.1158/1940-6207.CAPR-16-0209] [Cited by in Crossref: 152] [Cited by in F6Publishing: 85] [Article Influence: 25.3] [Reference Citation Analysis]
111 Cao L, Li WJ, Yang JH, Wang Y, Hua ZJ, Liu D, Chen YQ, Zhang HM, Zhang R, Zhao JS, Cheng SJ, Zhang Q. Inflammatory cytokine-induced expression of MASTL is involved in hepatocarcinogenesis by regulating cell cycle progression. Oncol Lett 2019;17:3163-72. [PMID: 30867746 DOI: 10.3892/ol.2019.9983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
112 Mohan CD, Rangappa S, Preetham HD, Chandra Nayaka S, Gupta VK, Basappa S, Sethi G, Rangappa KS. Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. Seminars in Cancer Biology 2020. [DOI: 10.1016/j.semcancer.2020.03.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
113 Schmidt-Arras D, Galun E, Rose-John S. The two facets of gp130 signalling in liver tumorigenesis. Semin Immunopathol 2021. [PMID: 34047814 DOI: 10.1007/s00281-021-00861-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Huang L, Liu D, Wang N, Ling S, Tang Y, Wu J, Hao L, Luo H, Hu X, Sheng L, Zhu L, Wang D, Luo Y, Shang Z, Xiao M, Mao X, Zhou K, Cao L, Dong L, Zheng X, Sui P, He J, Mo S, Yan J, Ao Q, Qiu L, Zhou H, Liu Q, Zhang H, Li J, Jin J, Fu L, Zhao W, Chen J, Du X, Qing G, Liu H, Liu X, Huang G, Ma D, Zhou J, Wang QF. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res 2018;28:172-86. [PMID: 29148541 DOI: 10.1038/cr.2017.146] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
115 Ortega Ó, Ondo-Méndez A, Garzón R. [STAT3 activation by hypoxia in in vitro models of cervix cancer and endothelial cells]. Biomedica 2017;37:119-30. [PMID: 28527256 DOI: 10.7705/biomedica.v37i2.3225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
116 Marquardt JU, Thorgeirsson SS. Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care. Cancer Cell 2014;25:409-11. [PMID: 24735920 DOI: 10.1016/j.ccr.2014.03.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
117 Butler RM, McKenzie RC, Jones CL, Flanagan CE, Woollard WJ, Demontis M, Ferreira S, Tosi I, John S, Whittaker SJ, Mitchell TJ. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance. J Invest Dermatol 2019;139:1975-1984.e2. [PMID: 30910759 DOI: 10.1016/j.jid.2019.03.1130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
118 Fang B. Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers (Basel) 2014;6:494-525. [PMID: 24662938 DOI: 10.3390/cancers6010494] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
119 Nault JC, Zucman Rossi J. Molecular classification of hepatocellular adenomas. Int J Hepatol. 2013;2013:315947. [PMID: 23401783 DOI: 10.1155/2013/315947] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
120 Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, Zhang T, Cremaschi G, Gray NS, Cerchietti L. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat Commun 2017;8:14290. [PMID: 28134252 DOI: 10.1038/ncomms14290] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
121 Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J. Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology 2018;68:964-76. [PMID: 29572896 DOI: 10.1002/hep.29884] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
122 Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol 2014;27:420-32. [PMID: 24051694 DOI: 10.1038/modpathol.2013.148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
123 Nevzorova YA, Liedtke C. Sh(i)pping signals protect against Stat3-driven liver cancer. Hepatology. 2012;55:322-324. [PMID: 22190379 DOI: 10.1002/hep.24742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
124 Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Allen HL, De Franco E, McDonald TJ, Rajala H, Ramelius A, Barton J, Heiskanen K, Heiskanen-Kosma T, Kajosaari M, Murphy NP, Milenkovic T, Seppänen M, Lernmark Å, Mustjoki S, Otonkoski T, Kere J, Morgan NG, Ellard S, Hattersley AT. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 2014;46:812-4. [PMID: 25038750 DOI: 10.1038/ng.3040] [Cited by in Crossref: 285] [Cited by in F6Publishing: 269] [Article Influence: 35.6] [Reference Citation Analysis]
125 von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V, Groner B. Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. Curr Signal Transduct Ther 2013;8:193-202. [PMID: 25045345 DOI: 10.2174/1574362409666140206221931] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
126 Wang BX, Platanias LC, Fish EN. STAT Activation in Malignancies: Roles in Tumor Progression and in the Generation of Antineoplastic Effects of IFNs. Journal of Interferon & Cytokine Research 2013;33:181-8. [DOI: 10.1089/jir.2012.0154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
127 Yoneda N, Matsui O, Kitao A, Kozaka K, Kobayashi S, Sasaki M, Yoshida K, Inoue D, Minami T, Gabata T. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background. Radiographics 2016;36:2010-27. [PMID: 27740898 DOI: 10.1148/rg.2016160037] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 7.5] [Reference Citation Analysis]
128 Goltz D, Fischer HP. Current Proceedings in the Molecular Dissection of Hepatocellular Adenomas: Review and Hands-on Guide for Diagnosis. Int J Mol Sci 2015;16:20994-1007. [PMID: 26404250 DOI: 10.3390/ijms160920994] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
129 Kamimura D, Arima Y, Hirano T, Ogura H, Murakami M. IL-6 and Inflammatory Diseases. In: Yoshimoto T, Yoshimoto T, editors. Cytokine Frontiers. Tokyo: Springer Japan; 2014. pp. 53-78. [DOI: 10.1007/978-4-431-54442-5_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
130 Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J 2016;6:e397. [PMID: 26918361 DOI: 10.1038/bcj.2016.1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
131 Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218. [PMID: 23887712 DOI: 10.1038/ncomms3218] [Cited by in Crossref: 362] [Cited by in F6Publishing: 352] [Article Influence: 45.3] [Reference Citation Analysis]
132 McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D, Benveniste EN. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 2011;10:2384-2393. [PMID: 22027691 DOI: 10.1158/1535-7163.mct-11-0480] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
133 Park SK, Byun WS, Lee S, Han YT, Jeong YS, Jang K, Chung SJ, Lee J, Suh YG, Lee SK. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction. Biochem Pharmacol 2020;178:114053. [PMID: 32450253 DOI: 10.1016/j.bcp.2020.114053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
134 Groner B. Determinants of the extent and duration of STAT3 signaling. JAKSTAT 2012;1:211-5. [PMID: 24058775 DOI: 10.4161/jkst.21469] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
135 Ng SY, Jacobsen ED. Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies. Hematol Oncol Clin North Am 2019;33:657-68. [PMID: 31229161 DOI: 10.1016/j.hoc.2019.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Sellier H, Rébillard A, Guette C, Barré B, Coqueret O. How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT 2013;2:e24716. [PMID: 24069560 DOI: 10.4161/jkst.24716] [Cited by in Crossref: 21] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
137 Calderaro J, Nault JC, Balabaud C, Couchy G, Saint-paul M, Azoulay D, Mehdaoui D, Luciani A, Zafrani ES, Bioulac-sage P, Zucman-rossi J. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Mod Pathol 2016;29:43-50. [DOI: 10.1038/modpathol.2015.119] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
138 Tanita K, Sakura F, Nambu R, Tsumura M, Imanaka Y, Ohnishi H, Kato Z, Pan J, Hoshino A, Suzuki K, Yasutomi M, Umetsu S, Okada C, Takagi M, Imai K, Ohara O, Muise AM, Okada S, Morio T, Kanegane H. Clinical and Immunological Heterogeneity in Japanese Patients with Gain-of-Function Variants in STAT3. J Clin Immunol 2021;41:780-90. [PMID: 33501615 DOI: 10.1007/s10875-021-00975-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
139 Bayard Q, Caruso S, Couchy G, Rebouissou S, Bioulac Sage P, Balabaud C, Paradis V, Sturm N, de Muret A, Guettier C, Bonsang B, Copie C, Letouzé E, Calderaro J, Imbeaud S, Nault JC, Zucman-Rossi J. Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut 2020;69:1667-76. [PMID: 31907296 DOI: 10.1136/gutjnl-2019-319790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
140 Poli V, Camporeale A. STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance. Front Oncol 2015;5:121. [PMID: 26106584 DOI: 10.3389/fonc.2015.00121] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
141 van Rosmalen BV, Furumaya A, Klompenhouwer AJ, Tushuizen ME, Braat AE, Reinten RJ, Ligthart MAP, Haring MPD, de Meijer VE, van Voorthuizen T, Takkenberg RB, Dejong CHC, de Man RA, IJzermans JNM, Doukas M, van Gulik TM, Verheij J; Dutch Benign Liver Tumor Group and the PALGA group. Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course. Liver Int 2021. [PMID: 34155783 DOI: 10.1111/liv.14989] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
142 Shen S, Niso-Santano M, Adjemian S, Takehara T, Malik SA, Minoux H, Souquere S, Mariño G, Lachkar S, Senovilla L, Galluzzi L, Kepp O, Pierron G, Maiuri MC, Hikita H, Kroemer R, Kroemer G. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell 2012;48:667-80. [PMID: 23084476 DOI: 10.1016/j.molcel.2012.09.013] [Cited by in Crossref: 178] [Cited by in F6Publishing: 168] [Article Influence: 17.8] [Reference Citation Analysis]
143 Ma Y, Karunakaran T, Veeraraghavan VP, Mohan SK, Li S. Sesame Inhibits Cell Proliferation and Induces Apoptosis through Inhibition of STAT-3 Translocation in Thyroid Cancer Cell Lines (FTC-133). Biotechnol Bioproc E 2019;24:646-52. [DOI: 10.1007/s12257-019-0151-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
144 Couronné L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E, Vainchenker W, Merlio JP, Beylot-Barry M, Damm F, Stern MH, Gaulard P, Lamant L, Delabesse E, Merle-Beral H, Nguyen-Khac F, Fontenay M, Tilly H, Bastard C, Zucman-Rossi J, Bernard OA, Mercher T. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013;98:1748-52. [PMID: 23872306 DOI: 10.3324/haematol.2013.085068] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
145 Domoszlai T, Martincuks A, Fahrenkamp D, Schmitz-van de Leur H, Küster A, Müller-newen G. Consequences of the disease-related L78R mutation for dimerization and activity of STAT3. Journal of Cell Science. [DOI: 10.1242/jcs.137422] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
146 Don-Doncow N, Escobar Z, Johansson M, Kjellström S, Garcia V, Munoz E, Sterner O, Bjartell A, Hellsten R. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J Biol Chem 2014;289:15969-78. [PMID: 24755219 DOI: 10.1074/jbc.M114.564252] [Cited by in Crossref: 59] [Cited by in F6Publishing: 26] [Article Influence: 7.4] [Reference Citation Analysis]
147 Fagard R, Metelev V, Souissi I, Baran-Marszak F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT 2013;2:e22882. [PMID: 24058788 DOI: 10.4161/jkst.22882] [Cited by in Crossref: 49] [Cited by in F6Publishing: 68] [Article Influence: 6.1] [Reference Citation Analysis]
148 Aparicio-Siegmund S, Sommer J, Monhasery N, Schwanbeck R, Keil E, Finkenstädt D, Pfeffer K, Rose-John S, Scheller J, Garbers C. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget 2014;5:2131-48. [PMID: 24742922 DOI: 10.18632/oncotarget.1852] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
149 Walker S, Wang C, Walradt T, Hong BS, Tanner JR, Levinsohn JL, Goh G, Subtil A, Lessin SR, Heymann WR, Vonderheid EC, King BA, Lifton RP, Choi J. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood 2016;127:948-51. [PMID: 26702067 DOI: 10.1182/blood-2015-06-654277] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
150 Raft MB, Jørgensen EN, Vainer B. Gene mutations in hepatocellular adenomas. Histopathology 2015;66:910-21. [PMID: 25195525 DOI: 10.1111/his.12539] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
151 Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1704. [PMID: 31683891 DOI: 10.3390/cancers11111704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
152 Martínez-Pérez C, Kay C, Meehan J, Gray M, Dixon JM, Turnbull AK. The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer. J Pers Med 2021;11:1073. [PMID: 34834425 DOI: 10.3390/jpm11111073] [Reference Citation Analysis]
153 Bioulac-sage P, Cubel G, Balabaud C. Pathological diagnosis of hepatocellular adenoma in clinical practice. Diagnostic Histopathology 2011;17:521-9. [DOI: 10.1016/j.mpdhp.2011.10.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
154 Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S, Bioulac-Sage P, Letouzé E, Zucman-Rossi J; GENTHEP Investigators. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology 2017;152:880-894.e6. [PMID: 27939373 DOI: 10.1053/j.gastro.2016.11.042] [Cited by in Crossref: 168] [Cited by in F6Publishing: 144] [Article Influence: 28.0] [Reference Citation Analysis]
155 Oota S. Somatic mutations - Evolution within the individual. Methods 2020;176:91-8. [PMID: 31711929 DOI: 10.1016/j.ymeth.2019.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016;40:9-14. [PMID: 26336998 DOI: 10.1016/j.clinre.2015.07.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
157 Panipinto PM, Singh AK, Shaikh FS, Siegel RJ, Chourasia M, Ahmed S. Takinib Inhibits Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts by Targeting the Janus Kinase-Signal Transducer and Activator of Transcription 3 (JAK/STAT3) Pathway. Int J Mol Sci 2021;22:12580. [PMID: 34830460 DOI: 10.3390/ijms222212580] [Reference Citation Analysis]
158 Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH. Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology. 2012;56:1567-1574. [PMID: 22378061 DOI: 10.1002/hep.25674] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 8.9] [Reference Citation Analysis]
159 Thiem S, Pierce TP, Palmieri M, Putoczki TL, Buchert M, Preaudet A, Farid RO, Love C, Catimel B, Lei Z, Rozen S, Gopalakrishnan V, Schaper F, Hallek M, Boussioutas A, Tan P, Jarnicki A, Ernst M. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest 2013;123:767-81. [PMID: 23321674 DOI: 10.1172/JCI65086] [Cited by in Crossref: 25] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
160 Bioulac-Sage P, Sempoux C, Balabaud C. Hepatocellular Adenomas: Morphology and Genomics. Gastroenterol Clin North Am 2017;46:253-72. [PMID: 28506364 DOI: 10.1016/j.gtc.2017.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
161 Avalle L, Camporeale A, Camperi A, Poli V. STAT3 in cancer: A double edged sword. Cytokine 2017;98:42-50. [PMID: 28579221 DOI: 10.1016/j.cyto.2017.03.018] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 18.2] [Reference Citation Analysis]
162 Zhang L, Yang Z, Ma A, Qu Y, Xia S, Xu D, Ge C, Qiu B, Xia Q, Li J, Liu Y. Growth arrest and DNA damage 45G down-regulation contributes to Janus kinase/signal transducer and activator of transcription 3 activation and cellular senescence evasion in hepatocellular carcinoma. Hepatology 2014;59:178-89. [PMID: 23897841 DOI: 10.1002/hep.26628] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
163 Chang N, Ahn SH, Kong DS, Lee HW, Nam DH. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. Mol Cell Endocrinol 2017;451:53-65. [PMID: 28089821 DOI: 10.1016/j.mce.2017.01.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
164 Aparicio-Siegmund S, Garbers C. The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity. Cytokine Growth Factor Rev 2015;26:579-86. [PMID: 26195434 DOI: 10.1016/j.cytogfr.2015.07.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
165 Erdogan F, Qadree AK, Radu TB, Orlova A, de Araujo ED, Moriggl R, Gunning PT. Structural and mutational analysis of member-specific STAT functions. Biochim Biophys Acta Gen Subj 2021;:130058. [PMID: 34774983 DOI: 10.1016/j.bbagen.2021.130058] [Reference Citation Analysis]
166 Russell MA, Pigors M, Houssen ME, Manson A, Kelsell D, Longhurst H, Morgan NG. A novel de novo activating mutation in STAT3 identified in a patient with common variable immunodeficiency (CVID). Clin Immunol 2018;187:132-6. [PMID: 29180260 DOI: 10.1016/j.clim.2017.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
167 Wöss K, Simonović N, Strobl B, Macho-Maschler S, Müller M. TYK2: An Upstream Kinase of STATs in Cancer. Cancers (Basel) 2019;11:E1728. [PMID: 31694222 DOI: 10.3390/cancers11111728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
168 Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J. Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol. 2017;67:1074-1083. [PMID: 28733222 DOI: 10.1016/j.jhep.2017.07.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
169 Quetier I, Brezillon N, Duriez M, Massinet H, Giang E, Ahodantin J, Lamant C, Brunelle M-N, Soussan P, Kremsdorf D. Hepatitis B virus HBx protein impairs liver regeneration through enhanced expression of IL-6 in transgenic mice. Journal of hepatology. 2013;59:285-291. [PMID: 23542345 DOI: 10.1016/j.jhep.2013.03.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
170 Pilati C, Zucman-rossi J. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine & Growth Factor Reviews 2015;26:499-506. [DOI: 10.1016/j.cytogfr.2015.07.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
171 Védie AL, Sutter O, Ziol M, Nault JC. Molecular classification of hepatocellular adenomas: impact on clinical practice. Hepat Oncol 2018;5:HEP04. [PMID: 30302195 DOI: 10.2217/hep-2017-0023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
172 Hutchins AP, Diez D, Miranda-Saavedra D. Genomic and computational approaches to dissect the mechanisms of STAT3's universal and cell type-specific functions. JAKSTAT 2013;2:e25097. [PMID: 24416643 DOI: 10.4161/jkst.25097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
173 Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-13. [PMID: 22591296 DOI: 10.1056/NEJMoa1114885] [Cited by in Crossref: 456] [Cited by in F6Publishing: 269] [Article Influence: 45.6] [Reference Citation Analysis]
174 D'Amico S, Shi J, Martin BL, Crawford HC, Petrenko O, Reich NC. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. Genes Dev. 2018;32:1175-1187. [PMID: 30135074 DOI: 10.1101/gad.311852.118] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]